Pharmaceutical

Pharma's $158B U.S. Manufacturing Surge Market Trend Eli Lilly Novartis Roche Regeneron Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
BAFF-R CAR-T: CR 100% CAR-T Biotech PeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
Global Biopharma Layoffs May 2025 Layoffs Stay updated on recent global biopharma layoffs in May 2025 with Guideview. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.
Q1 Sales Surge for CAR-T Therapies: Up to 146% Market Trend CAR-T GuideView reviews the Q1 2025 sales performance of six FDA-approved CAR-T cell therapies. Highlights include Breyanzi’s 146% surge and Carvykti’s 135% rise, while Kymriah and Tecartus saw declines.
Oral Semaglutide: Clinical Trial Breakthroughs in Diabetes Treatment Semaglutide Discover how oral semaglutide (Rybelsus®) revolutionizes type 2 diabetes treatment with innovative formulation, clinical trial success, and promising benefits in glucose control, weight, and metabolic health.
70% Stop Medication, Oral GLP-1 as the Next Decisive Point? Semaglutide Explore the future of GLP-1 treatments as oral drugs emerge as a game changer amid high discontinuation rates. Discover key players, clinical results, and the challenges of developing small molecule GLP-1 receptor agonists.
Sirius Therapeutics & CRISPR Partner on $895M+ FXI siRNA Therapy Deal Sirius Therapeutics CRISPR Therapeutics Sirius Therapeutics partners with CRISPR Therapeutics in a $895M+ deal to develop and commercialize SRSD107, a next-gen long-acting FXI-targeted siRNA therapy for thrombosis and related diseases.
Novo Nordisk CEO Lars Fruergaard Jørgensen Resigns Novo Nordisk Novo Nordisk announces CEO Lars Fruergaard Jørgensen's resignation and leadership changes. Lars Rebien Sørensen joins the board as observer, signaling strategic transition amid market challenges.
Takeda's 2024 Financial report Market Trend Financial statements Takeda Takeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.
Mirador Therapeutics and its Success Mirador Therapeutics Mirador Therapeutics, founded by the same team behind the $10.8B acquisition of Prometheus Biosciences, raises $400M in Series A to advance precision medicine in immune diseases. Can they replicate their previous success?

< Pre 1...50 51 525354 55 56...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles